Ting Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ting Therapeutics is a private, pre-clinical stage biotech developing novel therapeutics to prevent chemotherapy-induced hearing loss. Founded by academic researchers, the company is repurposing and adapting oncology drugs to protect auditory function without interfering with antibiotic efficacy. It operates in a high-need, underserved market with no FDA-approved protective agents, positioning its lead candidates for significant impact if clinical development is successful.

OtologyHearing Loss

Technology Platform

Repurposing and adaptation of known drugs (initially from oncology) for otoprotection, with a focus on mechanisms that do not interfere with aminoglycoside antibiotic efficacy.

Opportunities

Addressing a complete unmet need with no FDA-approved competitors for aminoglycoside-induced hearing loss.

Successful development could lead to expansion into broader otoprotection markets, including other ototoxic chemotherapies (e.g., cisplatin) and noise-induced hearing loss, representing a multi-billion dollar potential.

Risk Factors

High translational risk moving from pre-clinical to clinical stages, undefined regulatory pathways for a novel endpoint, and complete dependence on securing external financing to continue operations.

Potential for drug candidates to fail in safety or efficacy trials.

Competitive Landscape

The direct competitive landscape for an approved drug is empty. However, several academic institutions and biotechs are researching otoprotectants, often focusing on antioxidant pathways. Ting's key claimed differentiation is avoiding interference with antibiotic efficacy, a hurdle for many historical candidates like sodium thiosulfate.

More companies in Small Molecule Drugs →More companies in United States →